Add to ORKGInhibition of fatty acid oxidation has been reported to be car-dioprotective against myocardial ischemic injury; however, re-cent studies have questioned whether the cardioprotection associated with putative fatty acid oxidation inhibitors, such as ranolazine and trimetazidine, are due to changes in substrate oxidation. Therefore, the goals of this study were to com-pare the effects of ranolazine with a new fatty acid oxidation inhibitor, CVT-4325 [(R)-1-(2-methylbenzo[d]thiazol-5-yloxy)-3-(4-((5-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)methyl)-piperazin-1-yl)propan-2-ol], on carbohydrate and fatty acid oxidation and on left ventricular (LV) function in the response to ischemia/reperfusion in rat isolated perfused hearts. Metabolic ...
AIMS: Doxorubicin is widely used against cancer; however, it can produce heart failure (HF). Among ...
© 2019 Published by Elsevier B.V.Abnormalities of myocardial energy metabolism appear as a common ba...
To assess the effects of ranolazine, a new antiischemic drug, on regional myocardium of the left ven...
A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac ...
Ranolazine is a clinically approved drug for treating cardiac ventricular dysrhythmias and angina. I...
Ranolazine, an anti-anginal drug, is a late Na+ channel current blocker that is also believed to att...
AbstractRanolazine, an anti-anginal drug, is a late Na+ channel current blocker that is also believe...
Ranolazine (RS-43285) has shown antianginal effects in clinical trials and cardiac anti-ischaemic ac...
Mitochondrial fatty acid oxidation (FAO) is involved in myocardial damage after cardiopulmonary resu...
ObjectivesThis study examined the hypothesis that the improvement in myocardial blood flow (MBF) wit...
AIMS: Doxorubicin is widely used against cancer; however, it can produce heart failure (HF). Among o...
Background and Purpose Trimetazidine, known as a metabolic modulator, is an anti-anginal drug used f...
Background Dronedarone (DR), a new antiarrhythmic drug designed to reduce amiodarone’s extracardiac ...
Fatty acid amide hydrolase (FAAH) inhibitor [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB...
The combined and relative contribution of glucose and fatty acid oxidation generates myocardial ener...
AIMS: Doxorubicin is widely used against cancer; however, it can produce heart failure (HF). Among ...
© 2019 Published by Elsevier B.V.Abnormalities of myocardial energy metabolism appear as a common ba...
To assess the effects of ranolazine, a new antiischemic drug, on regional myocardium of the left ven...
A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac ...
Ranolazine is a clinically approved drug for treating cardiac ventricular dysrhythmias and angina. I...
Ranolazine, an anti-anginal drug, is a late Na+ channel current blocker that is also believed to att...
AbstractRanolazine, an anti-anginal drug, is a late Na+ channel current blocker that is also believe...
Ranolazine (RS-43285) has shown antianginal effects in clinical trials and cardiac anti-ischaemic ac...
Mitochondrial fatty acid oxidation (FAO) is involved in myocardial damage after cardiopulmonary resu...
ObjectivesThis study examined the hypothesis that the improvement in myocardial blood flow (MBF) wit...
AIMS: Doxorubicin is widely used against cancer; however, it can produce heart failure (HF). Among o...
Background and Purpose Trimetazidine, known as a metabolic modulator, is an anti-anginal drug used f...
Background Dronedarone (DR), a new antiarrhythmic drug designed to reduce amiodarone’s extracardiac ...
Fatty acid amide hydrolase (FAAH) inhibitor [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB...
The combined and relative contribution of glucose and fatty acid oxidation generates myocardial ener...
AIMS: Doxorubicin is widely used against cancer; however, it can produce heart failure (HF). Among ...
© 2019 Published by Elsevier B.V.Abnormalities of myocardial energy metabolism appear as a common ba...
To assess the effects of ranolazine, a new antiischemic drug, on regional myocardium of the left ven...